ClinicalTrials.gg
CompletedNCT03038022Updated Jun 4, 2026Results posted

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

A Phase 2 interventional study of MGL-3196 (resmetirom) and Placebo in Heterozygous Familial Hypercholesterolemia, sponsored by Madrigal Pharmaceuticals, Inc.. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Madrigal Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands — 5 open to participants now, 7 under way, 4 of them phase 3. Hyperlipoproteinemia Type II · Netherlands.

Enrollment
22nd of 33
116 · median 153
Started
2017
with 1 other
Phase 2
10 of 35
none open now
Registered
21st of 35
by date

Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, this one is the 22nd largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2017, is one of 10 in phase 2, and was the 21st registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

5 of the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in participants with Heterozygous Familial Hypercholesterolemia (HeFH).

03

Conditions studied

  • Heterozygous Familial Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be willing to participate in the study and provide written ;
  • Male and female adults ≥18 years of age;
  • Female participants of child bearing potential with negative serum pregnancy (beta human chorionic gonadotropin) test who are not breastfeeding, do not plan to become pregnant during the study, and agree to use effective per locally agreed requirements; male participants who have sexual intercourse with a female partner of child bearing potential from the first dose of study drug until 1 month after study completion must either be surgically sterile (confirmed by documented azoospermia >90 days after the procedure) or agree to use a condom with spermicide. All male participants must agree not to donate sperm from the first dose of study drug until 1 month after study completion;
  • Must have a diagnosis of HeFH by genetic testing or by having met the diagnostic criteria for definite familial hypercholesterolemia outlined by the Simon Broome Register Group or World Health Organization/Dutch Lipid Network (score >8);
  • Must have had a fasting LDL-C (low density lipoprotein cholesterol) ≥2.6 mmol/L (100 mg/dL); and
  • Must be on a stable or maximally tolerated dose (≥4 weeks prior to screening) of an approved statin (rosuvastatin ≤40 mg daily, atorvastatin ≤80 mg daily), with or without ezetimibe. Patients intolerant to statins were allowed.

Exclusion criteria

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia
  • LDL or plasma apheresis within 2 months prior to randomization;
  • class III or IV heart failure, or known \<30%;
  • Uncontrolled cardiac arrhythmia, including confirmed corrected using Fridericia's formula >450 msec for males and >470 msec for females at the screening assessment;
  • Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft, or stroke within 3 months prior to randomization;
  • Type 1 diabetes, or newly diagnosed or uncontrolled type 2 diabetes ( >8%);
  • History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening; Note: Significant alcohol consumption is defined as average of >20 g/day in female participants and >30 g/day in male participants;
  • Hyperthyroidism;
  • Thyroid replacement therapy;
  • Hypothyroidism;
  • Evidence of chronic liver disease;
  • , as defined by the presence of hepatitis B surface antigen;
  • , as defined by the presence of hepatitis C virus (HCV) antibody (anti-HCV) and HCV ribonucleic acid (RNA). Participants with positive anti-HCV who test negative for HCV RNA at screening will be allowed to participate in the study;
  • Serum >1.5 x (ULN) (one repeat allowed);
  • Estimated \<60 mL/min;
  • Creatine kinase >3 x ULN (one repeat allowed);
  • History of biliary diversion;
  • Positive for infection;
  • History of malignant hypertension;
  • Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at screening or randomization and confirmed at an unscheduled visit;
  • Triglycerides >5.7 mmol/L (500 mg/dL) at screening and confirmed by repeat assessment;
  • Active, serious medical disease with likely \<2 years;
  • Active substance abuse, including inhaled or injection drugs within the year prior to screening;
  • Participation in an new drug trial within the 30 days prior to randomization; or
  • Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, or compromise the well-being of the participants.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    MGL-3196

    Study Drug

    Drug: MGL-3196 (resmetirom)

  • Placebo comparator
    Placebo

    Matching Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Percent Change in LDL-C From Baseline To Week 12

    LDL-C was determined by ultracentrifugation or direct measure. Least-squares (LS) mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

    Time frame: Baseline up to Week 12

Secondary outcomes

  1. Mean Change From Baseline to Week 12 of Free Thyroxine (T4)

    T4 was assessed at each study visit.

    Time frame: Baseline up to Week 12

  2. Mean Change From Baseline to Week 12 of Free Triiodothyronine (T3)

    Free T3 was assessed at each study visit.

    Time frame: Baseline up to Week 12

  3. Mean Change From Baseline to Week 12 of Thyrotropin (TSH)

    TSH was assessed at each study visit.

    Time frame: Baseline up to Week 12

  4. Mean Change From Baseline to Week 12 of Thyroxine Binding Globulin (TBG)

    TBG was assessed at all study visits except the Screening Visit.

    Time frame: Baseline up to Week 12

  5. Mean Change From Baseline to Week 12 of Reverse Triiodothyronine (T3)

    Reverse T3 was assessed at each study visit.

    Time frame: Baseline up to Week 12

  6. Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 12

    Non-HDL-C were determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor

    Time frame: Baseline up to Week 12

  7. Mean Percent Change In Triglycerides From Baseline To Week 12

    Triglycerides were determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

    Time frame: Baseline up to Week 12

  8. Mean Percent Change In Lipoprotein(a) (Lp[a]) From Baseline To Week 12

    Lp(a) was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

    Time frame: Baseline up to Week 12

  9. Mean Percent Change in Apolipoprotein CIII From Baseline to Week 12

    Apolipoprotein CIII was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

    Time frame: Baseline up to Week 12

  10. Mean Percent Change In Apolipoprotein B (ApoB) From Baseline To Week 12

    ApoB was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

    Time frame: Baseline up to Week 12

  11. Mean Percent Change in Apolipoprotein B/Apolipoprotein A1 (ApoB/ApoA1) Ratio From Baseline to Week 12

    The ApoB/ApoA1 ratio was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

    Time frame: Baseline up to Week 12

  12. Mean Percent Change In Cholesterol/HDL-C Ratio From Baseline to Week 12

    The Cholesterol/HDL-C Ratio was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

    Time frame: Baseline up to Week 12

  13. Absolute Change in LDL-C From Baseline to Week 12

    LDL-C was determined by ultracentrifugation or direct measure . Least-squares (LS) mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

    Time frame: Baseline up to Week 12

  14. Percent Change From Baseline in LDL-C at Week 2 and Week 4 in Patients in the 100 mg and the 60 mg Groups

    LDL-C was determined by ultracentrifugation or direct measure. Least-squares (LS) mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

    Time frame: Baseline to Week 2 and Week 4

  15. Percent Change in LDL-C From Baseline to Week 12 by Systemic Exposure Category

    The effect on percent change in LDL-C from baseline to Week 12 was determined by patient exposure category (higher/lower). Patients taking MGL-3196 were categorized into lower and higher exposure groups. Patients in the higher exposure group must either have had estimated Week 2 AUC ≥5,000 mg∙h/L, or if Week 2 AUC \<5,000 mg∙h/L but Week 4 pre-dose concentration \>1.5 ng/mL (if on 60 mg MGL-3196). All other patients were in the lower exposure group.

    Time frame: Baseline to Week 12

  16. Mean Change in Lipid Particle Concentration From Baseline To Week 12: Total LDL Particles

    The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for LDL Particles.

    Time frame: Baseline up to Week 12

  17. Mean Change in Lipid Particle Concentration From Baseline To Week 12: Small LDL Particles

    The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Small LDL Particles.

    Time frame: Baseline up to Week 12

  18. Mean Change in Lipid Particle Concentration From Baseline To Week 12: Intermediate LDL Particles

    The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Intermediate LDL Particles.

    Time frame: Baseline up to Week 12

  19. Mean Change in Lipid Particle Concentration From Baseline To Week 12: Large LDL Particles

    The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Large LDL Particles.

    Time frame: Baseline up to Week 12

  20. Mean Change in Lipid Particle Concentration From Baseline To Week 12:Total Very Low-Density Lipoprotein (VLDL) and Chylomicron Particles

    The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for VLDL and Chylomicron Particles.

    Time frame: Baseline up to Week 12

  21. Mean Change in Lipid Particle Concentration From Baseline To Week 12: Total HDL Particles

    The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Total HDL Particles.

    Time frame: Baseline up to Week 12

  22. Mean Change in Lipid Particle Concentration From Baseline To Week 12: LDL Particle Size

    The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for LDL Particle size.

    Time frame: Baseline up to Week 12

  23. Mean Change in Lipid Particle Concentration From Baseline To Week 12: VLDL Particle Size

    The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for VLDL Particle Size.

    Time frame: Baseline up to Week 12

  24. Mean Change in Lipid Particle Concentration From Baseline To Week 12: HDL Particle Size

    The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for HDL Particle Size.

    Time frame: Baseline up to Week 12

07

Results

Posted Dec 23, 2025

Participant flow

Participant flow — Overall Study
MilestoneMGL-3196Placebo
Started7838
Received at least 1 dose of study drug7838
Completed7236
Not completed62
Withdrew: Withdrawal by subject20
Withdrew: Adverse event42

Outcome measures

PrimaryMean Percent Change in LDL-C From Baseline To Week 12

LDL-C was determined by ultracentrifugation or direct measure. Least-squares (LS) mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · percent change
Mean Percent Change in LDL-C From Baseline To Week 12
percent changeMGL-3196Placebo
Mean Percent Change in LDL-C From Baseline To Week 12-10.6 ± 2.598.2 ± 3.71
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = <0.0001 · Mean difference (net): -18.8 · 95% CI -27.8 to -9.8
SecondaryMean Change From Baseline to Week 12 of Free Thyroxine (T4)

T4 was assessed at each study visit.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · ng/dL
Mean Change From Baseline to Week 12 of Free Thyroxine (T4)
ng/dLMGL-3196Placebo
Mean Change From Baseline to Week 12 of Free Thyroxine (T4)-0.268 ± 0.01300.009 ± 0.0185
SecondaryMean Change From Baseline to Week 12 of Free Triiodothyronine (T3)

Free T3 was assessed at each study visit.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · ng/L
Mean Change From Baseline to Week 12 of Free Triiodothyronine (T3)
ng/LMGL-3196Placebo
Mean Change From Baseline to Week 12 of Free Triiodothyronine (T3)-0.04 ± 0.0380.10 ± 0.054
SecondaryMean Change From Baseline to Week 12 of Thyrotropin (TSH)

TSH was assessed at each study visit.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · mIU/L
Mean Change From Baseline to Week 12 of Thyrotropin (TSH)
mIU/LMGL-3196Placebo
Mean Change From Baseline to Week 12 of Thyrotropin (TSH)-0.027 ± 0.06900.114 ± 0.0987
SecondaryMean Change From Baseline to Week 12 of Thyroxine Binding Globulin (TBG)

TBG was assessed at all study visits except the Screening Visit.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · mg/L
Mean Change From Baseline to Week 12 of Thyroxine Binding Globulin (TBG)
mg/LMGL-3196Placebo
Mean Change From Baseline to Week 12 of Thyroxine Binding Globulin (TBG)-2.31 ± 0.256-0.44 ± 0.367
SecondaryMean Change From Baseline to Week 12 of Reverse Triiodothyronine (T3)

Reverse T3 was assessed at each study visit.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · ng/dL
Mean Change From Baseline to Week 12 of Reverse Triiodothyronine (T3)
ng/dLMGL-3196Placebo
Mean Change From Baseline to Week 12 of Reverse Triiodothyronine (T3)-4.36 ± 0.392-0.58 ± 0.554
SecondaryMean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 12

Non-HDL-C were determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · percent change
Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 12
percent changeMGL-3196Placebo
Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 12-12.0 ± 2.417.5 ± 3.46
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = <0.0001 · Mean difference (net): -19.5 · 95% CI -27.9 to -11.1
SecondaryMean Percent Change In Triglycerides From Baseline To Week 12

Triglycerides were determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · percent change
Mean Percent Change In Triglycerides From Baseline To Week 12
percent changeMGL-3196Placebo
Mean Percent Change In Triglycerides From Baseline To Week 12-18.3 ± 3.247.2 ± 4.64
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = <0.0001 · Mean difference (net): -25.4 · 95% CI -36.7 to -14.2
SecondaryMean Percent Change In Lipoprotein(a) (Lp[a]) From Baseline To Week 12

Lp(a) was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · percent change
Mean Percent Change In Lipoprotein(a) (Lp[a]) From Baseline To Week 12
percent changeMGL-3196Placebo
Mean Percent Change In Lipoprotein(a) (Lp[a]) From Baseline To Week 12-21.8 ± 2.874.4 ± 4.11
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = <0.0001 · Mean difference (net): -26.3 · 95% CI -36.2 to -16.4
SecondaryMean Percent Change in Apolipoprotein CIII From Baseline to Week 12

Apolipoprotein CIII was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · percent change
Mean Percent Change in Apolipoprotein CIII From Baseline to Week 12
percent changeMGL-3196Placebo
Mean Percent Change in Apolipoprotein CIII From Baseline to Week 12-19.3 ± 2.93.4 ± 4.1
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = <0.0001 · Mean difference (net): -22.7 · 95% CI -32.6 to -12.8
SecondaryMean Percent Change In Apolipoprotein B (ApoB) From Baseline To Week 12

ApoB was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · percent change
Mean Percent Change In Apolipoprotein B (ApoB) From Baseline To Week 12
percent changeMGL-3196Placebo
Mean Percent Change In Apolipoprotein B (ApoB) From Baseline To Week 12-14.2 ± 1.663.8 ± 2.37
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = <0.0001 · Mean difference (net): -18.0 · 95% CI -23.7 to -12.2
SecondaryMean Percent Change in Apolipoprotein B/Apolipoprotein A1 (ApoB/ApoA1) Ratio From Baseline to Week 12

The ApoB/ApoA1 ratio was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · percent change
Mean Percent Change in Apolipoprotein B/Apolipoprotein A1 (ApoB/ApoA1) Ratio From Baseline to Week 12
percent changeMGL-3196Placebo
Mean Percent Change in Apolipoprotein B/Apolipoprotein A1 (ApoB/ApoA1) Ratio From Baseline to Week 12-5.0 ± 1.84.2 ± 2.5
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = 0.0037 · Mean difference (net): -9.1 · 95% CI -15.3 to -3.0
SecondaryMean Percent Change In Cholesterol/HDL-C Ratio From Baseline to Week 12

The Cholesterol/HDL-C Ratio was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · percent change
Mean Percent Change In Cholesterol/HDL-C Ratio From Baseline to Week 12
percent changeMGL-3196Placebo
Mean Percent Change In Cholesterol/HDL-C Ratio From Baseline to Week 12-3.5 ± 2.36.3 ± 3.3
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = 0.017 · Mean difference (net): -9.8 · 95% CI -17.8 to -1.8
SecondaryAbsolute Change in LDL-C From Baseline to Week 12

LDL-C was determined by ultracentrifugation or direct measure . Least-squares (LS) mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · mg/dL
Absolute Change in LDL-C From Baseline to Week 12
mg/dLMGL-3196Placebo
Absolute Change in LDL-C From Baseline to Week 12-17.0 ± 3.319.9 ± 4.74
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = <0.0001 · Mean difference (net): -27.0 · 95% CI -38.4 to -15.5
SecondaryPercent Change From Baseline in LDL-C at Week 2 and Week 4 in Patients in the 100 mg and the 60 mg Groups

LDL-C was determined by ultracentrifugation or direct measure. Least-squares (LS) mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.

Time frame:
Baseline to Week 2 and Week 4
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Week 2 and Week 4 in Patients in the 100 mg and the 60 mg Groups
percent changeMGL-3196Placebo
Week 2-16.6 (-22.6 to -10.6)1.6 (-3.2 to 6.5)
Week 4-9.8 (-16.3 to -3.4)0.1 (-5.2 to 5.4)
SecondaryPercent Change in LDL-C From Baseline to Week 12 by Systemic Exposure Category

The effect on percent change in LDL-C from baseline to Week 12 was determined by patient exposure category (higher/lower). Patients taking MGL-3196 were categorized into lower and higher exposure groups. Patients in the higher exposure group must either have had estimated Week 2 AUC ≥5,000 mg∙h/L, or if Week 2 AUC \<5,000 mg∙h/L but Week 4 pre-dose concentration \>1.5 ng/mL (if on 60 mg MGL-3196). All other patients were in the lower exposure group.

Time frame:
Baseline to Week 12
Reported as:
Mean · percent change
Percent Change in LDL-C From Baseline to Week 12 by Systemic Exposure Category
percent changeMGL-3196 Lower ExposureMGL-3196 Higher ExposurePlacebo
Percent Change in LDL-C From Baseline to Week 12 by Systemic Exposure Category-8.1 ± 3.71-13.0 ± 3.628.2 ± 3.71
Statistical analysis
  • MGL-3196 Lower Exposure vs Placebo · ANOVA · p = 0.0025 · Mean difference (net): -16.3 · 95% CI -26.7 to -5.9
  • MGL-3196 Higher Exposure vs Placebo · ANOVA · p = <0.0001 · Mean difference (net): -21.2 · 95% CI -31.4 to -10.9
SecondaryMean Change in Lipid Particle Concentration From Baseline To Week 12: Total LDL Particles

The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for LDL Particles.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · nmol/L
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Total LDL Particles
nmol/LMGL-3196Placebo
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Total LDL Particles1223 ± 3341428 ± 475
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = <0.0001 · Mean difference (net): -245.2 · 95% CI -363.7 to -126.7
SecondaryMean Change in Lipid Particle Concentration From Baseline To Week 12: Small LDL Particles

The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Small LDL Particles.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · nmol/L
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Small LDL Particles
nmol/LMGL-3196Placebo
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Small LDL Particles655 ± 214760 ± 265
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = 0.0067 · Mean difference (net): -99.4 · 95% CI -170.6 to -28.2
SecondaryMean Change in Lipid Particle Concentration From Baseline To Week 12: Intermediate LDL Particles

The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Intermediate LDL Particles.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · nmol/L
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Intermediate LDL Particles
nmol/LMGL-3196Placebo
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Intermediate LDL Particles157 ± 96168 ± 184
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = 0.5245 · Mean difference (net): -14.7 · 95% CI -60.5 to 31.0
SecondaryMean Change in Lipid Particle Concentration From Baseline To Week 12: Large LDL Particles

The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Large LDL Particles.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · nmol/L
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Large LDL Particles
nmol/LMGL-3196Placebo
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Large LDL Particles411 ± 247501 ± 302
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = 0.0034 · Mean difference (net): -135.3 · 95% CI -224.7 to -45.8
SecondaryMean Change in Lipid Particle Concentration From Baseline To Week 12:Total Very Low-Density Lipoprotein (VLDL) and Chylomicron Particles

The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for VLDL and Chylomicron Particles.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · nmol/L
Mean Change in Lipid Particle Concentration From Baseline To Week 12:Total Very Low-Density Lipoprotein (VLDL) and Chylomicron Particles
nmol/LMGL-3196Placebo
Mean Change in Lipid Particle Concentration From Baseline To Week 12:Total Very Low-Density Lipoprotein (VLDL) and Chylomicron Particles24.8 ± 18.537.3 ± 24.7
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = 0.0129 · Mean difference (net): -10.0 · 95% CI -17.9 to -2.2
SecondaryMean Change in Lipid Particle Concentration From Baseline To Week 12: Total HDL Particles

The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Total HDL Particles.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · micromol/L
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Total HDL Particles
micromol/LMGL-3196Placebo
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Total HDL Particles29.79 ± 4.69930.92 ± 5.940
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = 0.3088 · Mean difference (net): -0.77 · 95% CI -2.26 to 0.72
SecondaryMean Change in Lipid Particle Concentration From Baseline To Week 12: LDL Particle Size

The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for LDL Particle size.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · nm
Mean Change in Lipid Particle Concentration From Baseline To Week 12: LDL Particle Size
nmMGL-3196Placebo
Mean Change in Lipid Particle Concentration From Baseline To Week 12: LDL Particle Size20.94 ± 0.54620.89 ± 0.549
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = 0.6905 · Mean difference (net): 0.04 · 95% CI -0.15 to 0.23
SecondaryMean Change in Lipid Particle Concentration From Baseline To Week 12: VLDL Particle Size

The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for VLDL Particle Size.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · nm
Mean Change in Lipid Particle Concentration From Baseline To Week 12: VLDL Particle Size
nmMGL-3196Placebo
Mean Change in Lipid Particle Concentration From Baseline To Week 12: VLDL Particle Size52.27 ± 7.06351.33 ± 8.801
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = 0.5008 · Mean difference (net): 0.96 · 95% CI -1.86 to 3.78
SecondaryMean Change in Lipid Particle Concentration From Baseline To Week 12: HDL Particle Size

The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for HDL Particle Size.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · nm
Mean Change in Lipid Particle Concentration From Baseline To Week 12: HDL Particle Size
nmMGL-3196Placebo
Mean Change in Lipid Particle Concentration From Baseline To Week 12: HDL Particle Size9.30 ± 0.5899.19 ± 0.586
Statistical analysis
  • MGL-3196 vs Placebo · ANOVA · p = 0.1066 · Mean difference (net): 0.12 · 95% CI -0.03 to 0.26

Adverse events

Collected over Baseline (Day 1) up to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MGL-31960/78 (0%)0/78 (0%)65/78 (83.3%)
Placebo0/38 (0%)1/38 (2.6%)28/38 (73.7%)
Most frequent serious events
Most frequent serious events
EventMGL-3196Placebo
PyrexiaGeneral disorders0/781/38
Most frequent other events
Showing 10 of 19
Most frequent other events
EventMGL-3196Placebo
NauseaGastrointestinal disorders16/782/38
DiarrheaGastrointestinal disorders15/784/38
NasopharyngitisInfections and infestations10/786/38
HeadacheNervous system disorders10/786/38
MyalgiaMusculoskeletal and connective tissue disorders5/785/38
DizzinessNervous system disorders4/784/38
Alanine aminotransferase increasedInvestigations8/780/38
Aspartate aminotransferase increasedInvestigations8/780/38
Hepatic enzyme increasedInvestigations7/780/38
FatigueGeneral disorders7/782/38

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MGL-3196PlaceboTotal
<=18 years000
Between 18 and 65 years562581
>=65 years221335
Age, Continuous
Age, Continuous(years)MGL-3196PlaceboTotal
Mean56.4 ± 12.3859.1 ± 11.3357.3 ± 12.06
Sex: Female, Male
Sex: Female, Male(Participants)MGL-3196PlaceboTotal
Female391655
Male392261
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MGL-3196PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino7838116
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MGL-3196PlaceboTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White7837115
More than one race000
Unknown or Not Reported000
Baseline Low-density Lipoprotein Cholesterol (LDL-C) (Direct measure or ultracentrifugation)
Baseline Low-density Lipoprotein Cholesterol (LDL-C) (Direct measure or ultracentrifugation)(mg/dL)MGL-3196PlaceboTotal
Mean131.4 ± 47.24137.0 ± 57.53133.3 ± 50.65
Statin Use
Statin Use(Participants)MGL-3196PlaceboTotal
Atorvastatin401656
Rosuvastatin341751
Pravastatin112
None347
08

Study locations

13 sites
  • Madrigal Research Site
    Aalborg, Denmark
  • Madrigal Research Site
    Copenhagen, Denmark
  • Madrigal Research Site
    Esbjerg, Denmark
  • Madrigal Research Site
    Herlev, Denmark
  • Madrigal Research Site
    Viborg, Denmark
  • Madrigal Research Site
    Amsterdam, Netherlands
  • Madrigal Research Site
    Apeldoorn, Netherlands
  • Madrigal Research Site
    Goes, Netherlands
  • Madrigal Research Site
    Hoorn, Netherlands
  • Madrigal Research Site
    Nijmegen, Netherlands
  • Madrigal Research Site
    Zwijndrecht, Netherlands
  • Madrigal Research Site - 1
    Oslo, Norway
  • Madrigal Research Site - 2
    Oslo, Norway
09

References and documents

Publications

  • Hovingh GK, Klausen IC, Heggen E, McCarty K, Zhou R, Isaac BF, Taub R, Langslet G, Kastelein JJP. Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia. J Am Coll Cardiol. 2022 Mar 29;79(12):1220-1222. doi: 10.1016/j.jacc.2022.01.023. No abstract available. PubMed 35331419 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Jan 2018, 10 months.

Results were first posted in Dec 2025, 7 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2017
First posted
Jan 31, 2017
StartActual
Feb 23, 2017
Primary completionActual
Jan 15, 2018
CompletionActual
Jan 15, 2018
Results first posted
Dec 23, 2025
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03038022
Responsible party
Sponsor
First posted
Jan 31, 2017
Start date
Feb 23, 2017
Primary completion
Jan 15, 2018
Completion
Jan 15, 2018
Results posted
Dec 23, 2025
Last update
Jun 4, 2026

Study contacts

Rebecca Taub, MD
study director · Madrigal Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Resmetirom

Start the discussion